Cytarabine
- Generic Name
- Cytarabine
- Brand Names
- Cytosar, Vyxeos
- Drug Type
- Small Molecule
- Chemical Formula
- C9H13N3O5
- CAS Number
- 147-94-4
- Unique Ingredient Identifier
- 04079A1RDZ
- Background
A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra P...
- Indication
For the treatment of acute non-lymphocytic leukemia, acute lymphocytic leukemia and blast phase of chronic myelocytic leukemia.
...
- Associated Conditions
- Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia, Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Acute Promyelocytic Leukemia, Meningeal leukemia, Metastatic Malignant Neoplasm to the Leptomeninges, Non-Hodgkin's Lymphoma (NHL), Treatment-Related Acute Myeloid Leukemia, Blast phase Chronic myeloid leukemia
- Associated Therapies
- -
Induction Intensification in Treating Infants With Newly Diagnosed Acute Lymphoblastic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2014-02-14
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 221
- Registration Number
- NCT00002756
- Locations
- 🇺🇸
Children's Hospital Central California, Madera, California, United States
🇺🇸Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
🇺🇸Kaplan Cancer Center at St. Mary's Medical Center, West Palm Beach, Florida, United States
Combination Chemotherapy Followed By Donor Bone Marrow or Umbilical Cord Blood Transplant in Treating Children With Newly Diagnosed Juvenile Myelomonocytic Leukemia
- Conditions
- Interventions
- Drug: tipifarnibDrug: isotretinoinDrug: fludarabine phosphateDrug: cytarabineRadiation: radiation therapyDrug: cyclophosphamideBiological: anti-thymocyte globulinProcedure: allogeneic bone marrow transplantationProcedure: double-unit umbilical cord blood transplantationProcedure: umbilical cord blood transplantationOther: laboratory biomarker analysis
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-04-11
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 100
- Registration Number
- NCT00025038
- Locations
- 🇺🇸
Children's Oncology Group, Arcadia, California, United States
Combination Chemotherapy in Treating Children With Anaplastic Large Cell Lymphoma (ALCL 99)
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2022-05-31
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 885
- Registration Number
- NCT00006455
- Locations
- 🇫🇷
Institut Gustave Roussy, Villejuif, France
🇦🇹St. Anna Children's Hospital, Vienna, Austria
🇩🇪Kinderklinik, Giessen, Germany
Chemotherapy With or Without Gemtuzumab Ozogamicin in Treating Older Patients With Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2012-08-27
- Target Recruit Count
- 472
- Registration Number
- NCT00052299
- Locations
- 🇮🇹
Ospedale San Bortolo, Vicenza, Italy
🇳🇱Onze Lieve Vrouwe Gasthuis, Amsterdam, Netherlands
🇦🇹A. oe. Krankenhaus der Barmherzigen Schwestern Kinderabteilung, Linz, Austria
Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Older Patients With Refractory or Relapsed Intermediate-Grade Non-Hodgkin's Lymphoma
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-07-03
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Registration Number
- NCT00002982
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Chemotherapy in Treating Children With Down Syndrome and Myeloproliferative Disorder, Acute Myelogenous Leukemia, or Myelodysplastic Syndrome
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-06-27
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 254
- Registration Number
- NCT00003593
- Locations
- 🇺🇸
Greenebaum Cancer Center at University of Maryland Medical Center, Baltimore, Maryland, United States
🇺🇸Naval Medical Center, Portsmouth, Portsmouth, Virginia, United States
🇺🇸Children's Memorial Hospital - Chicago, Chicago, Illinois, United States
Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Acute Lymphoblastic Leukemia
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-06-12
- Target Recruit Count
- 392
- Registration Number
- NCT00002700
- Locations
- 🇸🇰
Institute of Hematology & Transfusiology, University Hospital, Bratislava, Slovakia
🇧🇪Hopital Universitaire Erasme, Brussels, Belgium
🇧🇪Universitair Ziekenhuis Antwerpen, Edegem, Belgium
Tretinoin, Cytarabine, and Daunorubicin Hydrochloride With or Without Arsenic Trioxide Followed by Tretinoin With or Without Mercaptopurine and Methotrexate in Treating Patients With Acute Promyelocytic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-06-05
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 420
- Registration Number
- NCT00003934
- Locations
- 🇺🇸
Cancer and Leukemia Group B, Chicago, Illinois, United States
🇺🇸Comprehensive Cancer Center of Wake Forest University, Winston-Salem, North Carolina, United States
Combination Chemotherapy With or Without PSC 833, Peripheral Stem Cell Transplantation, and/or Interleukin-2 in Treating Patients With Acute Myeloid Leukemia
- Conditions
- Adult Acute Eosinophilic LeukemiaAdult Acute Erythroid Leukemia (M6)Adult Acute Megakaryoblastic Leukemia (M7)Adult Acute Basophilic LeukemiaAdult Acute Minimally Differentiated Myeloid Leukemia (M0)Adult Acute Monoblastic Leukemia (M5a)Adult Acute Monoblastic Leukemia and Acute Monocytic Leukemia (M5)Adult Acute Monocytic Leukemia (M5b)Adult Acute Myeloblastic Leukemia With Maturation (M2)Adult Acute Myeloblastic Leukemia Without Maturation (M1)
- Interventions
- Drug: cytarabineBiological: aldesleukinOther: clinical observationDrug: daunorubicin hydrochlorideBiological: filgrastimDrug: etoposideOther: pharmacological studyDrug: valspodarDrug: busulfanProcedure: autologous hematopoietic stem cell transplantationProcedure: peripheral blood stem cell transplantation
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-06-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 720
- Registration Number
- NCT00006363
- Locations
- 🇺🇸
Cancer and Leukemia Group B, Chicago, Illinois, United States
Imatinib Mesylate Plus Cytarabine in Treating Patients With Chronic Myelogenous Leukemia
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2016-01-07
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 24
- Registration Number
- NCT00022490
- Locations
- 🇺🇸
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸OHSU Knight Cancer Institute, Portland, Oregon, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.